Related Experiment Videos
Renal clearance of ifosfamide
J Springate1, M J Zamlauski-Tucker, H Lu
1Department of Pediatrics, State University of New York at Buffalo, USA.
Abstract:
Nephrotoxicity is an important clinical side effect of the chemotherapeutic agent ifosfamide. This medication is activated by the hepatic cytochrome P450 system with potentially toxic metabolites produced through both ring hydroxylation and chloroethyl side chain oxidation pathways. Using an isolated perfused rat kidney preparation, we examined the possibility that renal metabolism of ifosfamide also occurs. Renal function before and after addition of ifosfamide to perfusate was not significantly different. After addition of ifosfamike to the perfusate, the metabolites N2-dechloroethylifosfamide, N3-dechloroethylifosfamide, and isophasphoramide mustard were recovered from urine and renal venous effluent. These results provide the first demonstration of ifosfamide metabolism by the kidney and suggest the possibility that intrarenal metabolism may contribute to nephrotoxicity.
Insights
Ifosfamide, a chemotherapy drug, can harm the kidneys. This study shows the kidney itself can metabolize ifosfamide, potentially contributing to this nephrotoxicity.
Area of Science:
- Pharmacology
- Nephrology
- Drug Metabolism
Background:
- Ifosfamide is a widely used chemotherapy agent.
- Nephrotoxicity is a significant clinical side effect associated with ifosfamide treatment.
- Hepatic cytochrome P450 enzymes are known to activate ifosfamide, producing toxic metabolites.
Purpose of the Study:
- To investigate the potential for renal metabolism of ifosfamide.
- To determine if the kidney plays a role in the activation or breakdown of ifosfamide.
Main Methods:
- Utilized an isolated perfused rat kidney model.
- Administered ifosfamide to the perfusate and monitored renal function.
- Analyzed urine and renal venous effluent for ifosfamide metabolites.
Main Results:
- Renal function remained stable before and after ifosfamide administration.
- Identified key ifosfamide metabolites, including N2-dechloroethylifosfamide, N3-dechloroethylifosfamide, and isophasphoramide mustard, in the effluent.
- Detected these metabolites in both urine and renal venous effluent.
Conclusions:
- This study provides the first evidence of ifosfamide metabolism occurring within the kidney.
- Intrarenal metabolism of ifosfamide may be a contributing factor to its observed nephrotoxicity.
- Further research is warranted to elucidate the precise mechanisms and clinical implications.